NEW YORK (360Dx) – Breathalyzer-based diagnostic firm Owlstone Medical today said it has raised approximately $11.6 million in an investment round.

Existing investors participated in the round, which will go toward a commercial launch of Owlstone's breath biomarker R&D services, including the opening of a new high-volume clinical facility, the Cambridge, UK-based company said. Funds will also be used for ongoing clinical trials in lung and colon cancer screening.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.